



- (72) ROTHE, MIKE, US
(72) CAO, ZHAODAN, US
(72) REGNIER, CATHERINE, US
(71) TULARIK INC., US
(51) Int.Cl.⁷ C12N 9/12, C12Q 1/48
(30) 1997/07/01 (08/887,115) US
(30) 1997/07/10 (08/890,854) US
(54) **PROTEINES IKK- α , ACIDES NUCLEIQUES ET PROCÉDES**
(54) **IKK- α PROTEINS, NUCLEIC ACIDS AND METHODS**

(57) Cette invention concerne des procédés et des compositions concernant une kinase I κ B, IKK- α et les acides nucléiques associées. On peut produire les polypeptides par recombinaison à partir de cellules hôtes transformées tirées des acides nucléiques codant IKK- α décrits ou les purifier à partir de cellules humaines. Cette invention concerne également des sondes et des amorces d'hybridation de IKK- α isolées capables d'une hybridation spécifique avec les gènes IKK- α décrits, des agents de liaison spécifiques à IKK- α , tels que des anticorps spécifiques, ainsi que des procédés de production et d'utilisation de ces compositions en diagnostic, en thérapie et dans l'industrie biopharmaceutique.

(57) The invention provides methods and compositions relating to an I κ B kinase, IKK- α , and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK- α encoding nucleic acids or purified from human cells. The invention provides isolated IKK- α hybridization probes and primers capable of specifically hybridizing with the disclosed IKK- α genes, IKK- α -specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/12, C12Q 1/48	A1	(11) International Publication Number: WO 99/01541 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/13782 (22) International Filing Date: 1 July 1998 (01.07.98) (30) Priority Data: 08/887,115 1 July 1997 (01.07.97) US 08/890,854 10 July 1997 (10.07.97) US (71) Applicant: TULARIK INC. [US/US]; Two Corporate Drive, South San Francisco, CA 94080 (US). (72) Inventors: ROTHE, Mike; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). CAO, Zhaodan; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). REGNIER, Catherine; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). (74) Agent: OSMAN, Richard, Aron; Science & Technology Law Group, 75 Denise Drive, Hillsborough, CA 94010 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: IKK- α PROTEINS, NUCLEIC ACIDS AND METHODS		
(57) Abstract <p>The invention provides methods and compositions relating to an IκB kinase, IKK-α, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-α encoding nucleic acids or purified from human cells. The invention provides isolated IKK-α hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-α genes, IKK-α-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.</p>		

IKK- α Proteins, Nucleic Acids and Methods

INTRODUCTION

Field of the Invention

The field of this invention is proteins involved in transcription factor activation.

5

Background

Cytokines trigger changes in gene expression by modifying the activity of otherwise latent transcription factors (Hill and Treisman, 1995). Nuclear factor κ B (NF- κ B) is a prominent example of how such an external stimulus is converted into an active transcription factor (Verma et al., 1995). The NF- κ B system is composed of homo- and heterodimers of members of the Rel family of related transcription factors that control the expression of numerous immune and inflammatory response genes as well as important viral genes (Lenardo and Baltimore, 1989; Baeuerle and Henkel, 1994). The activity of NF- κ B transcription factors is regulated by their subcellular localization (Verma et al., 1995). In most cell types, NF- κ B is present as a heterodimer comprising of a 50 kDa and a 65 kDa subunit. This heterodimer is sequestered in the cytoplasm in association with I κ B α a member of the I κ B family of inhibitory proteins (Finco and Baldwin, 1995; Thanos and Maniatis, 1995; Verma et al., 1995). I κ B α masks the nuclear localization signal of NF- κ B and thereby prevents NF- κ B nuclear translocation. Conversion of NF- κ B into an active transcription factor that translocates into the nucleus and binds to cognate DNA sequences requires the phosphorylation and subsequent ubiquitin-dependent degradation of I κ B α in the 26s proteasome. Signal-induced phosphorylation of I κ B α occurs at serines 32 and 36. Mutation of one or both of these serines renders I κ B α resistant to ubiquitination and proteolytic degradation (Chen et al., 1995).

10

15

25

30

The pleiotropic cytokines tumor necrosis factor (TNF) and interleukin-1 (IL-1) are among the physiological inducers of I κ B phosphorylation and subsequent NF- κ B activation (Osborn et al., 1989; Beg et al., 1993). Although TNF and IL-1 initiate signaling cascades leading to NF- κ B activation via distinct families of cell-surface receptors (Smith et al., 1994; Dinarello, 1996), both pathways utilize members of the TNF receptor-associated factor (TRAF) family of adaptor proteins as signal transducers (Rothe et al., 1995; Hsu et al., 1996; Cao et al., 1996b). TRAF proteins were originally found to

WO 99/01541

PCT/US98/13782

associate directly with the cytoplasmic domains of several members of the TNF receptor family including the 75 kDa TNF receptor (TNFR2), CD40, CD30, and the lymphotoxin- β receptor (Rothe et al., 1994; Hu et al., 1994; Cheng et al., 1995; Mosialos et al., 1995; Song and Donner, 1995; Sato et al., 1995; Lee et al., 1996; Gedrich et al., 1996; Ansieau et al., 1996). In addition, TRAF proteins are recruited indirectly to the 55 kDa TNF receptor (TNFR1) by the adaptor protein TRADD (Hsu et al., 1996). Activation of NF- κ B by TNF requires TRAF2 (Rothe et al., 1995; Hsu et al., 1996). TRAF5 has also been implicated in NF- κ B activation by members of the TNF receptor family (Nakano et al., 1996). In contrast, TRAF6 participates in NF- κ B activation by IL-1 (Cao et al., 1996b). Upon IL-1 treatment, TRAF6 associates with IRAK, a serine-threonine kinase that binds to the IL-1 receptor complex (Cao et al., 1996a).

The NF- κ B-inducing kinase (NIK) is a member of the MAP kinase kinase kinase (MAP3K) family that was identified as a TRAF2-interacting protein (Malinin et al., 1997). NIK activates NF- κ B when overexpressed, and kinase-inactive mutants of NIK comprising its TRAF2-interacting C-terminal domain (NIK₍₆₂₄₋₉₄₇₎) or lacking two crucial lysine residues in its kinase domain (NIK_(KK429-430AA)) behave as dominant-negative inhibitors that suppress TNF-, IL-1-, and TRAF2-induced NF- κ B activation (Malinin et al., 1997). Recently, NIK was found to associate with additional members of the TRAF family, including TRAF5 and TRAF6. Catalytically inactive mutants of NIK also inhibited TRAF5- and TRAF6-induced NF- κ B activation, thus providing a unifying concept for NIK as a common mediator in the NF- κ B signaling cascades triggered by TNF and IL-1 downstream of TRAFs.

Here, we disclose a novel human kinase I κ B Kinase, IKK- α , as a NIK-interacting protein. IKK- α has sequence similarity to the conceptual translate of a previously identified open reading frame (SEQ ID NO:5) postulated to encode a serine-threonine kinase of unknown function ('Conserved Helix-loop-helix Ubiquitous Kinase' or CHUK, Connelly and Marcu, 1995; Mock et al., 1995). Catalytically inactive mutants of IKK- α are shown to suppress NF- κ B activation induced by TNF and IL-1 stimulation as well as by TRAF and NIK overexpression; transiently expressed IKK- α is shown to associate with the endogenous I κ B α complex; and IKK- α is shown to phosphorylate I κ B α on serines 32 and 36.

SUMMARY OF THE INVENTION

The invention provides methods and compositions relating to isolated IKK- α polypeptides, related nucleic acids, polypeptide domains thereof having IKK- α -specific structure and activity and modulators of IKK- α function, particularly I κ B kinase activity. IKK- α polypeptides can regulate NF κ B activation and hence provide important regulators of cell function. The polypeptides may be produced recombinantly from transformed host cells from the subject IKK- α polypeptide encoding nucleic acids or purified from mammalian cells. The invention provides isolated IKK- α hybridization probes and primers capable of specifically hybridizing with the disclosed IKK- α gene, IKK- α -specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for IKK- α transcripts), therapy (e.g. IKK- α kinase inhibitors to inhibit TNF signal transduction) and in the biopharmaceutical industry (e.g. as immunogens, reagents for isolating other transcriptional regulators, reagents for screening chemical libraries for lead pharmacological agents, etc.).

DETAILED DESCRIPTION OF THE INVENTION

The nucleotide sequence of a natural cDNA encoding a human IKK- α polypeptide is shown as SEQ ID NO:3, and the full conceptual translate is shown as SEQ ID NO:4. The IKK- α polypeptides of the invention include incomplete translates of SEQ ID NO:3, particularly of SEQ ID NO:3, residues 1-638, which translates and deletion mutants of SEQ ID NO:4 have human IKK- α -specific amino acid sequence, binding specificity or function and comprise at least one of Cys30, GluLeu604, Thr679, Ser680, Pro684, Thr686, and Ser678. Preferred translates/deletion mutants comprise at least a 6 residue Cys30, Glu543, Leu604, Thr679, Ser680, Pro684, Thr686 or Ser687-containing domain of SEQ ID NO:4, preferably including at least 8, more preferably at least 12, most preferably at least 20 contiguous residues which immediately flank said residue, with said residue preferably residing within said contiguous residues, see, e.g. Table I; which mutants provide hIKK- α specific epitopes and immunogens.

TABLE 1. Exemplary IKK- α polypeptides having IKK- α binding specificity

hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 1-30) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 686-699)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 22-31) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 312-345)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 599-608) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 419-444)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 601-681) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 495-503)
5 hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 604-679) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 565-590)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 670-687) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 610-627)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 679-687) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 627-638)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 680-690) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 715-740)
hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 684-695) hIKK- $\alpha\Delta$ 1 (SEQ ID NO:4, residues 737-745)

10 The subject domains provide IKK- α domain specific activity or function, such as
IKK- α -specific kinase or kinase inhibitory activity, NIK-binding or binding inhibitory
activity, I κ B-binding or binding inhibitory activity, NF κ B activating or inhibitory activity
or antibody binding. Preferred domains phosphorylate at least one and preferably both the
serine 32 and 36 of I κ B (Verma, I. M., et al. (1995)). As used herein, Ser32 and Ser36 of
15 I κ B refers collectively to the two serine residues which are part of the consensus sequence
DSGL/IXSM/L (e.g. ser 32 and 36 in I κ B α , ser 19 and 23 in I κ B β , and ser 157 and 161,
or 18 and 22, depending on the usage of methionines, in I κ B ϵ , respectively.

IKK- α -specific activity or function may be determined by convenient *in vitro*, cell-
based, or *in vivo* assays: e.g. *in vitro* binding assays, cell culture assays, in animals (e.g.
20 gene therapy, transgenics, etc.), etc. Binding assays encompass any assay where the
molecular interaction of an IKK- α polypeptide with a binding target is evaluated. The
binding target may be a natural intracellular binding target such as an IKK- α substrate, a
IKK- α regulating protein or other regulator that directly modulates IKK- α activity or its
localization; or non-natural binding target such a specific immune protein such as an
25 antibody, or an IKK- α specific agent such as those identified in screening assays such as
described below. IKK- α -binding specificity may assayed by kinase activity or binding
equilibrium constants (usually at least about 10^7 M $^{-1}$, preferably at least about 10^8 M $^{-1}$,
more preferably at least about 10^9 M $^{-1}$), by the ability of the subject polypeptide to function
as negative mutants in IKK- α -expressing cells, to elicit IKK- α specific antibody in a
30 heterologous host (e.g a rodent or rabbit), etc. In any event, the IKK- α binding specificity

of the subject IKK- α polypeptides necessarily distinguishes the murine and human CHUK sequences of Connelly and Marcu (1995) as well as IKK- β (SEQ ID NO:4).

The claimed IKK- α polypeptides are isolated or pure: an "isolated" polypeptide is unaccompanied by at least some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, and more preferably at least about 5% by weight of the total polypeptide in a given sample and a pure polypeptide constitutes at least about 90%, and preferably at least about 99% by weight of the total polypeptide in a given sample. In a particular embodiments, IKK- α polypeptides are isolated from a MKP-1 precipitable complex, isolated from a IKK complex, and/or isolated from IKK- β . The IKK- α polypeptides and polypeptide domains may be synthesized, produced by recombinant technology, or purified from mammalian, preferably human cells. A wide variety of molecular and biochemical methods are available for biochemical synthesis, molecular expression and purification of the subject compositions, see e.g. Molecular Cloning, A Laboratory Manual (Sambrook, *et al.* Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, *et al.*, Greene Publ. Assoc., Wiley-Interscience, NY) or that are otherwise known in the art.

The invention provides binding agents specific to IKK polypeptides, preferably the claimed IKK- α polypeptides, including substrates, agonists, antagonists, natural intracellular binding targets, etc., methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, specific binding agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with improper utilization of a pathway involving the subject proteins, e.g. NF- κ B activation. Novel IKK-specific binding agents include IKK-specific receptors, such as somatically recombined polypeptide receptors like specific antibodies or T-cell antigen receptors (see, e.g. Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory) and other natural intracellular binding agents identified with assays such as one-, two- and three-hybrid screens, non-natural intracellular binding agents identified in screens of chemical libraries such as described below, etc. Agents of particular interest modulate IKK function, e.g. IKK-dependent transcriptional activation. For example, a wide variety of inhibitors of IKK I κ B kinase activity may be used to regulate signal transduction involving I κ B. Exemplary IKK I κ B kinase inhibitors include known classes of serine/threonine kinase (e.g. PKC)

WO 99/01541

PCT/US98/13782

inhibitors such as competitive inhibitors of ATP and substrate binding, antibiotics, IKK-derived peptide inhibitors, etc., see Tables II and III. IKK specificity and activity are readily quantified in high throughput kinase assays using panels of protein kinases (see cited references and Examples).

Preferred inhibitors include natural compounds such as staurosporine (Omura S, et al. J Antibiot (Tokyo) 1995 Jul;48(7):535-48), produced by a marine organism, and synthetic compounds such as PD 153035, which also potently inhibits the EGF receptor protein kinase (Fry DW et al. Science 1994 Aug 19;265(5175):1093-5). Members of the tyrphostin family of synthetic protein kinase inhibitors are also useful; these include compounds which are pure ATP competitors, compounds which are pure substrate competitors, and compounds which are mixed competitors: compete with both ATP and substrate (Levitzki A and Gazit A, Science 1995 Mar 24;267(5205):1782-8). Additional IKK inhibitors include peptide-based substrate competitors endogenously made by the mammalian cell, e.g. PKI (protein kinase inhibitor, Seasholtz AF et al., Proc Natl Acad Sci USA 1995 Feb 28;92(5):1734-8), or proteins inhibiting cdc kinases (Correa-Bordes J and Nurse P, Cell 1995 Dec 15;83(6):1001-9). Additional small peptide based substrate competitive kinase inhibitors and allosteric inhibitors (inhibitory mechanisms independent of ATP or substrate competition) are readily generated by established methods (Hvalby O, et al. Proc Natl Acad Sci USA 1994 May 24;91(11):4761-5; Barja P, et al., Cell Immunol 1994 Jan;153(1):28-38; Villar-Palasi C, Biochim Biophys Acta 1994 Dec 30;1224(3):384-8; Liu WZ, et al., Biochemistry 1994 Aug 23;33(33):10120-6).

TABLE II. Selected Small Molecule IKK Kinase Inhibitors

HA-100 ¹	Iso-H7 ¹²	A-3 ¹⁸
Chelerythrine ²	PKC 19-31	HA1004 ^{19,20}
Staurosporine ^{3,4,5}	H-7 ^{13,3,14}	K-252a ^{16,5}
25 Calphostin C ^{6,7,8,9}	H-89 ¹⁵	KT5823 ¹⁶
K-252b ¹⁰	KT5720 ¹⁶	ML-9 ²¹
PKC 19-36 ¹¹	cAMP-depPKinhib ¹⁷	KT5926 ²²

Citations

1. Hagiwara, M., et al. Mol. Pharmacol. 32: 7 (1987)
- 30 2. Herbert, J. M., et al. Biochem Biophys Res Com 172: 993 (1990)
3. Schachtele, C., et al. Biochem Biophys Res Com 151: 542 (1988)

WO 99/01541

PCT/US98/13782

4. Tamaoki, T., et al. *Biochem Biophys Res Com* 135: 397 (1986)
5. Tischler, A. S., et al. *J. Neurochemistry* 55: 1159 (1990)
6. Bruns, R. F., et al. *Biochem Biophys Res Com* 176: 288 (1991)
7. Kobayashi, E., et al. *Biochem Biophys Res Com* 159: 548 (1989)
8. Tamaoki, T., et al. *Adv2nd Mass Phosphoprotein Res* 24:497(1990)
- 5 9. Tamaoki, T., et al. *Biotechnology* 8: 732 (1990)
10. Yasuzawa, T. *J. Antibiotics* 39: 1972 (1986)
11. House, C., et al. *Science* 238: 1726 (1987)
12. Quick, J., et al. *Biochem. Biophys. Res. Com.* 167: 657 (1992)
13. Bouli, N. M. and Davis, M. *Brain Res.* 525: 198 (1990)
- 10 14. Takahashi, I., et al. *J. Pharmacol. Exp. Ther.* 255: 1218 (1990)
15. Chijiwa, T., et al. *J. Biol. Chem.* 265: 5267 (1990)
16. Kase, H., et al. *Biochem. Biophys. Res. Com.* 142: 436 (1987)
17. Cheng, H. C., et al. *J. Biol. Chem.* 261: 989 (1986)
18. Inagaki, M., et al. *Mol. Pharmacol.* 29: 577 (1986)
- 15 19. Asano, T. and Hidaka, H. *J Pharmaco. Exp Ther* 231:141 (1984)
20. Hidaka, H., et al. *Biochemistry* 23: 5036 (1984)
21. Nagatsu, T., et al. *Biochem Biophys Res Com* 143:1045 (1987)
22. Nakanishi, S., et al. *Mol. Pharmacol.* 37: 482 (1990)

20 TABLE III. Selected Peptidyl IKK Kinase Inhibitors

hI κ B α , residues 24-39, 32Ala	hIKK- α , Δ 5-203
hI κ B α , residues 29-47, 36Ala	hIKK- α , Δ 1-178
hI κ B α , residues 26-46, 32/36Ala	hIKK- α , Δ 368-756
hI κ B β , residues 25-38, 32Ala	hIKK- α , Δ 460-748
25 hI κ B β , residues 30-41, 36Ala	hIKK- α , Δ 1-289
hI κ B β , residues 26-46, 32/36Ala	hIKK- α , Δ 12-219
hI κ B ϵ , residues 24-40, 32Ala	hIKK- α , Δ 307-745
hI κ B ϵ , residues 31-50, 36Ala	hIKK- α , Δ 319-644
hI κ B ϵ , residues 27-44, 32/36Ala	

30 Accordingly, the invention provides methods for modulating signal transduction

WO 99/01541

PCT/US98/13782

involving I κ B in a cell comprising the step of modulating IKK kinase activity, e.g. by contacting the cell with a serine/threonine kinase inhibitor. The cell may reside in culture or in situ, i.e. within the natural host. Preferred inhibitors are orally active in mammalian hosts. For diagnostic uses, the inhibitors or other IKK binding agents are frequently labeled, such as with fluorescent, radioactive, chemiluminescent, or other easily detectable molecules, either conjugated directly to the binding agent or conjugated to a probe specific for the binding agent.

The amino acid sequences of the disclosed IKK- α polypeptides are used to back-translate IKK- α polypeptide-encoding nucleic acids optimized for selected expression systems (Holler et al. (1993) Gene 136, 323-328; Martin et al. (1995) Gene 154, 150-166) or used to generate degenerate oligonucleotide primers and probes for use in the isolation of natural IKK- α -encoding nucleic acid sequences ("GCG" software, Genetics Computer Group, Inc, Madison WI). IKK- α -encoding nucleic acids used in IKK- α -expression vectors and incorporated into recombinant host cells, e.g. for expression and screening, transgenic animals, e.g. for functional studies such as the efficacy of candidate drugs for disease associated with IKK- α -modulated cell function, etc.

The invention also provides nucleic acid hybridization probes and replication / amplification primers having a IKK- α cDNA specific sequence comprising at least 12, preferably at least 24, more preferably at least 36 and most preferably at least contiguous 96 bases of a strand of SEQ ID NO:3, particularly of SEQ ID NO:2, nucleotides 1-1913, and preferably including at least one of bases 1-92, 1811, 1812, 1992, 1995, 2034, 2035, 2039, 2040, 2050, 2055 and 2060, and sufficient to specifically hybridize with a second nucleic acid comprising the complementary strand of SEQ ID NO:3 in the presence of a third nucleic acid comprising (SEQ ID NO:5). Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5 x SSPE (0.18 M NaCl, 0.01 M NaPO₄, pH7.7, 0.001 M EDTA) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE buffer at 42°C. IKK- α nucleic acids can also be distinguished using alignment algorithms, such as BLASTX (Altschul *et al.* (1990) Basic Local Alignment Search Tool, J Mol Biol 215, 403-410).

The subject nucleic acids are of synthetic/non-natural sequences and/or are isolated, i.e. unaccompanied by at least some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, preferably at least about 5% by weight of total nucleic acid present in a given fraction, and usually recombinant, meaning they comprise a non-natural sequence or a natural sequence joined to
5 nucleotide(s) other than that which it is joined to on a natural chromosome. Recombinant nucleic acids comprising the nucleotide sequence of SEQ ID NO:3, or requisite fragments thereof, contain such sequence or fragment at a terminus, immediately flanked by (i.e. contiguous with) a sequence other than that which it is joined to on a natural chromosome, or flanked by a native flanking region fewer than 10 kb, preferably fewer than 2 kb, which
10 is at a terminus or is immediately flanked by a sequence other than that which it is joined to on a natural chromosome. While the nucleic acids are usually RNA or DNA, it is often advantageous to use nucleic acids comprising other bases or nucleotide analogs to provide modified stability, etc.

The subject nucleic acids find a wide variety of applications including use as
15 translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc.; use in detecting the presence of IKK- α genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional IKK- α homologs and structural analogs. In diagnosis, IKK- α hybridization probes find use in identifying wild-type and mutant IKK- α alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific
20 oligonucleotide (ASO) probes for high-throughput clinical diagnoses. In therapy, therapeutic IKK- α nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active IKK- α .

The invention provides efficient methods of identifying agents, compounds or lead compounds for agents active at the level of a IKK modulatable cellular function.
25 Generally, these screening methods involve assaying for compounds which modulate IKK interaction with a natural IKK binding target, in particular, IKK phosphorylation of I κ B-derived substrates, particularly I κ B and NIK substrates. A wide variety of assays for binding agents are provided including labeled *in vitro* protein-protein binding assays, immunoassays, cell based assays, etc. The methods are amenable to automated, cost-
30 effective high throughput screening of chemical libraries for lead compounds. Identified reagents find use in the pharmaceutical industries for animal and human trials; for example,

the reagents may be derivatized and rescreened in *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

In vitro binding assays employ a mixture of components including an IKK polypeptide, which may be part of a fusion product with another peptide or polypeptide, e.g. a tag for detection or anchoring, etc. The assay mixtures comprise a natural
5 intracellular IKK binding target. In a particular embodiment, the binding target is a substrate comprising I κ B serines 32 and/or 36. Such substrates comprise a I κ B α , β or ϵ peptide including the serine 32 and/or 36 residue and at least 5, preferably at least 10, and more preferably at least 20 naturally occurring immediately flanking residues on each side (e.g. for serine 36 peptides, residues 26-46, 22-42, or 12-32 or 151-171 for I κ B α , β or ϵ -
10 derived substrates, respectively). While native full-length binding targets may be used, it is frequently preferred to use portions (e.g. peptides) thereof so long as the portion provides binding affinity and avidity to the subject IKK polypeptide conveniently measurable in the assay. The assay mixture also comprises a candidate pharmacological agent. Candidate agents encompass numerous chemical classes, though typically they are organic
15 compounds; preferably small organic compounds and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. A variety of other reagents may also be included in the mixture. These include reagents like ATP or ATP analogs (for kinase assays), salts, buffers, neutral proteins, e.g. albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. may be used.

20 The resultant mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the IKK polypeptide specifically binds the cellular binding target, portion or analog with a reference binding affinity. The mixture components can be added in any order that provides for the requisite bindings and incubations may be performed at any temperature which facilitates optimal binding.
25 Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening.

After incubation, the agent-biased binding between the IKK polypeptide and one or more binding targets is detected by any convenient way. For IKK kinase assays, 'binding' is generally detected by a change in the phosphorylation of a IKK- α substrate. In this
30 embodiment, kinase activity may be quantified by the transfer to the substrate of a labeled phosphate, where the label may provide for direct detection as radioactivity, luminescence,

optical or electron density, etc. or indirect detection such as an epitope tag, etc. A variety of methods may be used to detect the label depending on the nature of the label and other assay components, e.g. through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc.

5 A difference in the binding affinity of the IKK polypeptide to the target in the absence of the agent as compared with the binding affinity in the presence of the agent indicates that the agent modulates the binding of the IKK polypeptide to the IKK binding target. Analogously, in the cell-based assay also described below, a difference in IKK- α -dependent transcriptional activation in the presence and absence of an agent indicates the agent modulates IKK function. A difference, as used herein, is statistically significant and preferably represents at least a 50%, more preferably at least a 90% difference.

10 The following experimental section and examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

15 Identification of IKK- α

To investigate the mechanism of NIK-mediated NF- κ B activation, we identified proteins that associate directly with NIK by yeast two-hybrid protein interaction cloning (Fields and Song, 1989). An expression vector was generated that encodes NIK fused to the DNA-binding domain of the yeast transcription factor GAL4. This vector was used as bait in a two-hybrid screen of a human B cell cDNA library. From approximately six million transformants, eight positive clones were obtained, as determined by activation of *his* and *lacZ* reporter genes. Of these clones, three encoded a member of the TRAF family, TRAF3 (Hu et al., 1994; Cheng et al., 1995; Mosialos et al., 1995; Sato et al., 1995) and one encoded a novel protein we call IKK- α . Retransformation into yeast cells verified the interaction between NIK and IKK- α . A full-length human IKK- α clone was isolated by screening a Jurkat cDNA library with a probe generated from the 5'-end of the IKK- α two-hybrid clone. IKK- α comprises an N-terminal serine-threonine kinase catalytic domain, a C-terminal helix-loop-helix domain and a leucine zipper-like amphipathic α -helix juxtaposed in between the helix-loop-helix and kinase domain.

30 Interaction of IKK- α and NIK in Human Cells

The interaction of IKK- α with NIK was confirmed in mammalian cell

coimmunoprecipitation assays. Human IKK- α containing an N-terminal Flag epitope tag was transiently coexpressed in 293 human embryonic kidney cells with Myc epitope-tagged NIK or HA epitope-tagged TRAF proteins. Cell lysates were immunoprecipitated using a monoclonal antibody against the Flag epitope, and coprecipitating NIK or TRAF proteins were detected by immunoblot analysis with an anti-Myc or anti-HA monoclonal antibodies.

5 In this assay, IKK- α was able to coprecipitate NIK confirming the interaction between both proteins as detected for IKK- α by yeast two-hybrid analysis. Also, a deletion mutant IKK- α protein lacking most of the N-terminal kinase domain (IKK- $\alpha_{(307-745)}$) was able to associate with NIK, indicating that the α -helical C-terminal half of IKK- α mediates the interaction with NIK. In contrast to NIK, IKK- α failed to associate with either TRAF2 or TRAF3. However,

10 when NIK was coexpressed with IKK- α and TRAF2, strong coprecipitation of TRAF2 with IKK- α was detected, indicating the formation of a ternary complex between IKK- α , NIK and TRAF2.

Effect of IKK- α and IKK- α Mutants on NF- κ B Activation

To investigate a possible role for IKK- α in NF- κ B activation, we examined if transient

15 overexpression of IKK- α might activate an NF- κ B-dependent reporter gene. An E-selectin-luciferase reporter construct (Schindler and Baichwal, 1994) and a IKK- α expression vector were cotransfected into HeLa cells. IKK- α expression activated the reporter gene in a dose-dependent manner, with a maximal induction of luciferase activity of about 6 to 7-fold compared to vector control. Similar results were obtained in 293 cells, where IKK- α

20 overexpression induced reporter gene activity approximately 4-fold. TNF treatment did not stimulate the weak NF- κ B-inducing activity of overexpressed IKK- α in reporter gene assays. Thus, IKK- α induces NF- κ B activation when overexpressed.

We next determined the effect of overexpression of kinase-inactive IKK- $\alpha_{(307-745)}$ that still associates with NIK on signal-induced NF- κ B activation in reporter gene assays in

25 293 cells. Overexpression of IKK- $\alpha_{(307-745)}$ blocked TNF- and IL-1-induced reporter gene activation similar to overexpression of NIK $_{(624-947)}$. IKK- $\alpha_{(307-745)}$ was also found to inhibit NF- κ B-dependent reporter gene activity elicited by overexpression of TRAF2, TRAF6 and NIK. Taken together these results demonstrate that a catalytically inactive IKK- α mutant is a dominant-negative inhibitor of TNF-, IL-1, TRAF- and NIK-induced NF- κ B

30 activation. This indicates that IKK- α functions as a common mediator of NF- κ B activation by TNF and IL-1 downstream of NIK.

Parentetical References

- Ansieau, S., et al. (1996). *Proc. Natl. Acad. Sci. USA* 93, 14053-14058.
- Baeuerle, P. A., and Henkel, T. (1994). *Annu. Rev. Immunol.* 12, 141-179.
- Beg, A. A., et al. (1993). *Mol. Cell. Biol.* 13, 3301-3310.
- Cao, Z., Henzel, W. J., and Gao, X. (1996a). *Science* 271, 1128-1131.
- 5 Cao, Z., et al. (1996b). *Nature* 383, 443-446.
- Chen, Z., et al. (1995). *Genes Dev.* 9, 1586-1597.
- Cheng, G., et al. (1995). *Science* 267, 1494-1498.
- Connelly, M. A., and Marcu, K. B. (1995). *Cell. Mol. Biol. Res.* 41, 537-549.
- Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. *Blood* 87, 2095-2147.
- 10 Fields, S., and Song, O.-k. (1989). *Nature* 340, 245-246.
- Finco, T. S., and Baldwin, A. S. (1995). *Immunity* 3, 263-272.
- Gedrich, R. W., et al. (1996). *J. Biol. Chem.* 271, 12852-12858.
- Hill, C. S., and Treisman, R. (1995). *Cell* 80, 199-211.
- Hsu, H., Shu, H.-B., Pan, M.-P., and Goeddel, D. V. (1996). *Cell* 84, 299-308.
- 15 Hu, H. M., et al. (1994). *J. Biol. Chem.* 269, 30069-30072.
- Lee, S. Y., et al. (1996). *Proc. Natl. Acad. Sci. USA* 93, 9699-9703.
- Lenardo, M., and Baltimore, D. (1989). *Cell* 58, 227-229.
- Malinin, N. L., et al. (1997). *Nature* 385, 540-544.
- Mock et al. (1995). *Genomics* 27, 348-351.
- 20 Mosialos, G., et al. (1995). *Cell* 80, 389-399.
- Nakano, H., et al. (1996). *J. Biol. Chem.* 271, 14661-14664.
- Osborn, L., Kunkel, S., and Nabel, G. J. (1989). *Proc. Natl. Acad. Sci. USA* 86, 2336-2340.
- Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995). *Science* 269, 1424-1427.
- Rothe, M., Wong, S. C., Henzel, W. J., and Goeddel, D. V. (1994). *Cell* 78, 681-692.
- 25 Sato, T., Irie, S., and Reed, J. C. (1995). *FEBS Lett.* 358, 113-118.
- Schindler, U., and Baichwal, V. R. (1994). *Mol. Cell. Biol.* 14, 5820-5831.
- Smith, C. A., Farrah, T., and Goodwin, R. G. (1994). *Cell* 76, 959-962.
- Song, H. Y., and Donner, D. B. (1995). *Biochem. J.* 809, 825-829.
- Thanos, D., and Maniatis, T. (1995). *Cell* 80, 529-532.
- 30 Verma, I. M., et al. (1995). *Genes Dev.* 9, 2723-2735.

EXAMPLES

1. Protocol for at IKK- α - I κ B α phosphorylation assay.

A. Reagents:

- Neutralite Avidin: 20 μ g/ml in PBS.

- kinase: 10^{-8} - 10^{-5} M IKK- α (SEQ ID NO:4) at 20 μ g/ml in PBS.

5 - substrate: 10^{-7} - 10^{-4} M biotinylated substrate (21 residue peptide consisting of residues 26-46 of human I κ B α) at 40 μ g/ml in PBS.

- Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature.

- Assay Buffer: 100 mM KCl, 10 mM MgCl₂, 1 mM MnCl₂, 20 mM HEPES pH 7.4, 0.25 mM EDTA, 1% glycerol, 0.5% NP-40, 50 mM BME, 1 mg/ml BSA, cocktail of protease
10 inhibitors.

- [³²P] γ -ATP 10x stock: 2 x 10^{-5} M cold ATP with 100 μ Ci [³²P] γ -ATP. Place in the 4°C microfridge during screening.

- Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin
15 (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVo₃ (Sigma # S-6508) in 10 ml of PBS.

B. Preparation of assay plates:

- Coat with 120 μ l of stock N Avidin per well overnight at 4°C.

- Wash 2 times with 200 μ l PBS.

20 - Block with 150 μ l of blocking buffer.

- Wash 2 times with 200 μ l PBS.

C. Assay:

- Add 40 μ l assay buffer/well.

- Add 40 μ l biotinylated substrate (2-200 pmoles/40 μ l in assay buffer)

25 - Add 40 μ l kinase (0.1-10 pmoles/40 μ l in assay buffer)

- Add 10 μ l compound or extract.

- Add 10 μ l [³²P] γ -ATP 10x stock.

- Shake at 25°C for 15 minutes.

- Incubate additional 45 minutes at 25°C.

30 - Stop the reaction by washing 4 times with 200 μ l PBS.

- Add 150 μ l scintillation cocktail.

WO 99/01541

PCT/US98/13782

- Count in Topcount.

D. Controls for all assays (located on each plate):

a. Non-specific binding

b. cold ATP at 80% inhibition.

5 2. Protocol for high throughput IKK- α -NIK binding assay.

A. Reagents:

- Neutralite Avidin: 20 μ g/ml in PBS.

- Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature.

10 - Assay Buffer: 100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM β -mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors.

- ³³P IKK- α polypeptide 10x stock: 10⁻⁸ - 10⁻⁶ M "cold" IKK- α supplemented with 200,000-250,000 cpm of labeled IKK- α (Beckman counter). Place in the 4°C microfridge during screening.

15 - Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVO₃ (Sigma # S-6508) in 10 ml of PBS.

- NIK: 10⁻⁷ - 10⁻⁵ M biotinylated NIK in PBS.

B. Preparation of assay plates:

20 - Coat with 120 μ l of stock N-Avidin per well overnight at 4°C.

- Wash 2 times with 200 μ l PBS.

- Block with 150 μ l of blocking buffer.

- Wash 2 times with 200 μ l PBS.

C. Assay:

25 - Add 40 μ l assay buffer/well.

- Add 10 μ l compound or extract.

- Add 10 μ l ³³P-IKK- α (20-25,000 cpm/0.1-10 pmoles/well = 10⁻⁹- 10⁻⁷ M final conc).

- Shake at 25°C for 15 minutes.

- Incubate additional 45 minutes at 25°C.

30 - Add 40 μ M biotinylated NIK (0.1-10 pmoles/40 μ l in assay buffer)

- Incubate 1 hour at room temperature.

WO 99/01541

PCT/US98/13782

- Stop the reaction by washing 4 times with 200 μ M PBS.
- Add 150 μ M scintillation cocktail.
- Count in Topcount.

D. Controls for all assays (located on each plate):

- a. Non-specific binding
- 5 b. Soluble (non-biotinylated NIK) at 80% inhibition.

10 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

WO 99/01541

PCT/US98/13782

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Rothe, Mike
Cao, Zhaodan
Régnier, Catherine
- (ii) TITLE OF INVENTION: IKK- α Proteins, Nucleic Acids and Methods
- 10 (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
15 (A) ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
(B) STREET: 268 BUSH STREET, SUITE 3200
(C) CITY: SAN FRANCISCO
(D) STATE: CALIFORNIA
(E) COUNTRY: USA
(F) ZIP: 94104
- 20 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
30 (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: OSMAN, RICHARD A
(B) REGISTRATION NUMBER: 36,627
35 (C) REFERENCE/DOCKET NUMBER: T97-006-1
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (415) 343-4341
40 (B) TELEFAX: (415) 343-4342
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2268 base pairs

WO 99/01541

PCT/US98/13782

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	ATGAGCTGGT CACCTTCCCT GACAACGCAG ACATGTGGGG CCTGGGAAAT GAAAGAGCGC	60
	CTTGGGACAG GGGGATTTGG AAATGTCATC CGATGGCACA ATCAGGAAAC AGGTGAGCAG	120
	ATTGCCATCA AGCAGTGCCG GCAGGAGCTC AGCCCCCGGA ACCGAGAGCG GTGGTGCCTG	180
10	GAGATCCAGA TCATGAGAAG GCTGACCCAC CCCAATGTGG TGGCTGCCCC AGATGTCCCT	240
	GAGGGGATGC AGAACTTGGC GCCCAATGAC CTGCCCTGC TGGCCATGGA GTECTGCCAA	300
	GGAGGAGATC TCCGGAAGTA CCTGAACCAG TTTGAGAACT GCTGTGGTCT GCGGGAAGGT	360
	GCCATCCTCA CCTTGCTGAG TGACATTGCC TCTGCGCTTA GATACCTTCA TGAAAACAGA	420
	ATCATCCATC GGGATCTAAA GCCAGAAAAC ATCGTCCTGC AGCAAGGAGA ACAGAGGTTA	480
15	ATACACAAAA TTATTGACCT AGGATATGCC AAGGAGCTGG ATCAGGGCAG TCTTTGCACA	540
	TCATTGCTGG GGACCCTGCA GTACCTGGCC CCAGAGCTAC TGGAGCAGCA GAAGTACACA	600
	GTGACCGTCG ACTACTGGAG CTTCGGCACC CTGGCCTTTG AGTGCATCAC GGGCTTCCGG	660
	CCCTTCCTCC CCAACTGGCA GCCCGTGCAG TGGCATTCAA AAGTGCGGCA GAAGAGTGAG	720
	GTGGACATTG TTGTTAGCGA AGACTTGAAT GGAACGGTGA AGTTTTCAAG CTCTTTACCC	780
20	TACCCCAATA ATCTTAACAG TGTCTGGCT GAGCGACTGG AGAAGTGGCT GCAACTGATG	840
	CTGATGTGGC ACCCCCGACA GAGGGGCACG GATCCCACGT ATGGGCCCAA TGGCTGCTTC	900
	AAGGCCCTGG ATGACATCTT AAACCTAAAG CTGGTTTATA TCTTGAACAT GGTACCGGC	960
	ACCATCCACA CCTACCCTGT GACAGAGGAT GAGAGTCTGC AGAGCTTGAA GGCCAGAATC	1020
	CAACAGGACA CGGGCATCCC AGAGGAGGAC CAGGAGCTGC TGCAGGAAGC GGGCCTGGCG	1080
25	TTGATCCCCG ATAAGCCTGC CACTCAGTGT ATTTTCAGACG GCAAGTTAAA TGAGGGCCAC	1140
	ACATTGGACA TGGATCTTGT TTTTCTCTTT GACAACAGTA AAATCACCTA TGAGACTCAG	1200
	ATCTCCCCAC GGCCCCAACC TGAAAGTGTC AGCTGTATCC TTCAAGAGCC CAAGAGGAAT	1260
	CTCGCCTTCT TCCAGCTGAG GAAGGTGTGG GGCCAGGTCT GGCACAGCAT CCAGACCCTG	1320
	AAGGAAGATT GCAACCGGCT GCAGCAGGGA CAGCGAGCCG CCATGATGAA TCTCCTCCGA	1380
30	AACAACAGCT GCCTCTCCAA AATGAAGAAT TCCATGGCTT CCATGTCTCA GCAGCTCAAG	1440
	GCCAAGTTGG ATTTCTTCAA AACCAGCATC CAGATTGACC TGGAGAAGTA CAGCGAGCAA	1500
	ACCGAGTTTG GGATCACATC AGATAAACTG CTGCTGGCCT GGAGGGAAAT GGAGCAGGCT	1560
	GTGGAGCTCT GTGGGCGGGA GAACGAAGTG AAACCTCCTGG TAGAACGGAT GATGGCTCTG	1620
	CAGACCGACA TTGTGGACTT ACAGAGGAGC CCCATGGGCC GGAAGCAGGG GGGAACGCTG	1680
35	GACGACCTAG AGGAGCAAGC AAGGGAGCTG TACAGGAGAC TAAGGGAAAA ACCTCGAGAC	1740
	CAGCGAACTG AGGGTGACAG TCAGGAAATG GTACGGCTGC TGCTTCAGGC AATTCAGAGC	1800
	TTCGAGAAGA AAGTGCGAGT GATCTATACG CAGCTCAGTA AAACCTGTGGT TTGCAAGCAG	1860
	AAGGCGCTGG AACTGTTGCC CAAGGTGGAA GAGGTGGTGA GCTTAATGAA TGAGGATGAG	1920
	AAGACTGTTG TCCGGCTGCA GGAGAAGCGG CAGAAGGAGC TCTGGAATCT CCTGAAGATT	1980
40	GCTTGTAGCA AGGTCCGTGG TCCTGTCAGT GGAAGCCCGG ATAGCATGAA TGCCTCTCGA	2040
	CTTAGCCAGC CTGGGCAGCT GATGTCTCAG CCCTCCACGG CCTCCAACAG CTTACCTGAG	2100
	CCAGCCAAGA AGAGTGAAGA ACTGGTGGCT GAAGCACATA ACCTCTGCAC CCTGCTAGAA	2160
	AATGCCATAC AGGACACTGT GAGGGAACAA GACCAGAGTT TCACGGCCCT AGACTGGAGC	2220
	TGGTTACAGA CGGAAGAAGA AGAGCACAGC TGCCTGGAGC AGGCCTCA	2268

WO 99/01541

PCT/US98/13782

	625		630		635		640
	Lys Thr Val Val Arg Leu Gln Glu Lys Arg Gln Lys Glu Leu Trp Asn						
			645		650		655
	Leu Leu Lys Ile Ala Cys Ser Lys Val Arg Gly Pro Val Ser Gly Ser						
			660		665		670
5	Pro Asp Ser Met Asn Ala Ser Arg Leu Ser Gln Pro Gly Gln Leu Met						
			675		680		685
	Ser Gln Pro Ser Thr Ala Ser Asn Ser Leu Pro Glu Pro Ala Lys Lys						
			690		695		700
	Ser Glu Glu Leu Val Ala Glu Ala His Asn Leu Cys Thr Leu Leu Glu						
10	705		710		715		720
	Asn Ala Ile Gln Asp Thr Val Arg Glu Gln Asp Gln Ser Phe Thr Ala						
			725		730		735
	Leu Asp Trp Ser Trp Leu Gln Thr Glu Glu Glu Glu His Ser Cys Leu						
			740		745		750
15	Glu Gln Ala Ser						
			755				

(2) INFORMATION FOR SEQ ID NO:3:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2238 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	ATGGAGCGGC CCCCGGGGCT GCGGCCGGGC GCGGGCGGGC CCTGGGAGAT GCGGGAGCGG	60
30	CTGGGCACCG GCGGCTTCGG GAACGTCTGT CTGTACCAGC ATCGGGAAC TGTATCTCAA	120
	ATAGCAATTA AGTCTTGTCT CCTAGAGCTA AGTACCAAAA ACAGAGAACG ATGGTGCCAT	180
	GAAATCCAGA TTATGAAGAA GTTGAACCAT GCCAATGTTG TAAAGGCCTG TGTATGTTCT	240
	GAAGAATTGA ATATTTTGAT TCATGATGTG CCTCTTCTAG CAATGGAATA CTGTTCTGGA	300
	GGAGATCTCC GAAAGCTGCT CAACAAACCA GAAAATTGTT GTGGACTTAA AGAAAGCCAG	360
35	ATACTTTCTT TACTAAGTGA TATAGGGTCT GGGATTCGAT ATTTGCATGA AAACAAAATT	420
	ATACATCGAG ATCTAAAACC TGAAAACATA GTTCTTCAGG ATGTTGGTGG AAAGATAATA	480
	CATAAAATAA TTGATCTGGG ATATGCCAAA GATGTTGATC AAGGAAGTCT GTGTACATCT	540
	TTTGTGGGAA CACTGCAGTA TCTGGCCCA GAGCTCTTTG AGAATAAGCC TTACACAGCC	600
	ACTGTTGATT ATTGGAGCTT TGGGACCATG GTATTTGAAT GTATTGCTGG ATATAGGCCT	660
40	TTTTTGCATC ATCTGCAGCC ATTTACCTGG CATGAGAAGA TTAAGAAGAA GGATCCAAAG	720
	TGTATATTTG CATGTGAAGA GATGTCAGGA GAAGTTCGGT TTAGTAGCCA TTTACCTCAA	780
	CCAAATAGCC TTTGTAGTTT AATAGTAGAA CCCATGGAAA ACTGGCTACA GTTGATGTTG	840
	AATTGGGACC CTCAGCAGAG AGGAGGACCT GTTGACCTTA CTTTGAAGCA GCCAAGATGT	900
	TTTGTATTAA TGGATCACAT TTTGAATTTG AAGATAGTAC ACATCCTAAA TATGACTTCT	960

WO 99/01541

PCT/US98/13782

GCAAAGATAA TTTCTTTTCT GTTACCACCT GATGAAAGTC TTCATTCACT ACAGTCTCGT 1020
 ATTGAGCGTG AAACCTGGAAT AAATACTGGT TCTCAAGAAC TTCTTTCAGA GACAGGAATT 1080
 TCTCTGGATC CTCGGAAACC AGCCTCTCAA TGTGTTCTAG ATGGAGTTAG AGGCTGTGAT 1140
 AGCTATATGG TTTATTTGTT TGATAAAAGT AAAACTGTAT ATGAAGGGCC ATTTGCTTCC 1200
 AGAAGTTTAT CTGATTGTGT AAATTATATT GTACAGGACA GCAAAATACA GCTTCCAATT 1260
 5 ATACAGCTGC GTAAAGTGTG GGCTGAAGCA GTGCACTATG TGTCTGGACT AAAAGAAGAC 1320
 TATAGCAGGC TCTTTCAGGG ACAAAGGGCA GCAATGTTAA GTCTTCTTAG ATATAATGCT 1380
 AACTTAACAA AAATGAAGAA CACTTTGATC TCAGCATCAC AACAACTGAA AGCTAAATTG 1440
 GAGTTTTTTC ACAAAGCAT TCAGCTTGAC TTGGAGAGAT ACAGCGAGCA GATGACGTAT 1500
 GGGATATCTT CAGAAAAAAT GCTAAAAGCA TGGAAAGAAA TGGAAAGAAA GGCCATCCAC 1560
 10 TATGCTGAGG TTGGTGTCTAT TGGATACCTG GAGGATCAGA TTATGTCTTT GCATGCTGAA 1620
 ATCATGGAGC TACAGAAGAG CCCCTATGGA AGACGTCAGG GAGACTTGAT GGAATCTCTG 1680
 GAACAGCGTG CCATTGATCT ATATAAGCAG TTAAAACACA GACCTTCAGA TCACTCCTAC 1740
 AGTGACAGCA CAGAGATGGT GAAAATCATT GTGCACACTG TGCAGAGTCA GGACCGTGTG 1800
 CTCAAGGAGC TGTTTGGTCA TTTGAGCAAG TTGTTGGGCT GTAAGCAGAA GATTATTGAT 1860
 15 CTACTCCCTA AGGTGGAAGT GGCCCTCAGT AATATCAAAG AAGCTGACAA TACTGTCTATG 1920
 TTCATGCAGG GAAAAAGGCA GAAAGAAATA TGGCATCTCC TTAAAATTGC CTGTACACAG 1980
 AGTTCTGCCC GGTCCCTTGT AGGATCCAGT CTAGAAGGTG CAGTAACCCC TCAGACATCA 2040
 GCATGGCTGC CCCCAGCTTC AGCAGAACAT GATCATTCTC TGTCATGTGT GGTAACCTCT 2100
 CAAGATGGGG AGACTTCAGC ACAAATGATA GAAGAAAATT TGAAGTGCCT TGGCCATTTA 2160
 20 AGCACTATTA TTCATGAGGC AAATGAGGAA CAGGGCAATA GTATGATGAA TCTTGATTGG 2220
 AGTTGGTTAA CAGAATGA 2238

(2) INFORMATION FOR SEQ ID NO:4:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 745 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

35 Met Glu Arg Pro Pro Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu
 1 5 10 15
 Met Arg Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn Val Cys Leu Tyr
 20 25 30
 Gln His Arg Glu Leu Asp Leu Lys Ile Ala Ile Lys Ser Cys Arg Leu
 40 35 40 45
 Glu Leu Ser Thr Lys Asn Arg Glu Arg Trp Cys His Glu Ile Gln Ile
 50 55 60
 Met Lys Lys Leu Asn His Ala Asn Val Val Lys Ala Cys Asp Val Pro
 65 70 75 80

WO 99/01541

PCT/US98/13782

		435		440		445											
	Arg	Ala	Ala	Met	Leu	Ser	Leu	Leu	Arg	Tyr	Asn	Ala	Asn	Leu	Thr	Lys	
		450		455							460						
	Met	Lys	Asn	Thr	Leu	Ile	Ser	Ala	Ser	Gln	Gln	Leu	Lys	Ala	Lys	Leu	
	465			470						475					480		
5	Glu	Phe	Phe	His	Lys	Ser	Ile	Gln	Leu	Asp	Leu	Glu	Arg	Tyr	Ser	Glu	
				485						490					495		
	Gln	Met	Thr	Tyr	Gly	Ile	Ser	Ser	Glu	Lys	Met	Leu	Lys	Ala	Trp	Lys	
				500					505					510			
	Glu	Met	Glu	Glu	Lys	Ala	Ile	His	Tyr	Ala	Glu	Val	Gly	Val	Ile	Gly	
10				515					520					525			
	Tyr	Leu	Glu	Asp	Gln	Ile	Met	Ser	Leu	His	Ala	Glu	Ile	Met	Glu	Leu	
	530			535							540						
	Gln	Lys	Ser	Pro	Tyr	Gly	Arg	Arg	Gln	Gly	Asp	Leu	Met	Glu	Ser	Leu	
	545			550							555					560	
15	Glu	Gln	Arg	Ala	Ile	Asp	Leu	Tyr	Lys	Gln	Leu	Lys	His	Arg	Pro	Ser	
				565						570					575		
	Asp	His	Ser	Tyr	Ser	Asp	Ser	Thr	Glu	Met	Val	Lys	Ile	Ile	Val	His	
				580					585					590			
	Thr	Val	Gln	Ser	Gln	Asp	Arg	Val	Leu	Lys	Glu	Leu	Phe	Gly	His	Leu	
20				595					600					605			
	Ser	Lys	Leu	Leu	Gly	Cys	Lys	Gln	Lys	Ile	Ile	Asp	Leu	Leu	Pro	Lys	
	610			615								620					
	Val	Glu	Val	Ala	Leu	Ser	Asn	Ile	Lys	Glu	Ala	Asp	Asn	Thr	Val	Met	
	625			630							635					640	
25	Phe	Met	Gln	Gly	Lys	Arg	Gln	Lys	Glu	Ile	Trp	His	Leu	Leu	Lys	Ile	
				645						650					655		
	Ala	Cys	Thr	Gln	Ser	Ser	Ala	Arg	Ser	Leu	Val	Gly	Ser	Ser	Leu	Glu	
				660					665					670			
	Gly	Ala	Val	Thr	Pro	Gln	Thr	Ser	Ala	Trp	Leu	Pro	Pro	Thr	Ser	Ala	
30				675					680					685			
	Glu	His	Asp	His	Ser	Leu	Ser	Cys	Val	Val	Thr	Pro	Gln	Asp	Gly	Glu	
	690			695								700					
	Thr	Ser	Ala	Gln	Met	Ile	Glu	Glu	Asn	Leu	Asn	Cys	Leu	Gly	His	Leu	
	705			710							715					720	
35	Ser	Thr	Ile	Ile	His	Glu	Ala	Asn	Glu	Glu	Gln	Gly	Asn	Ser	Met	Met	
				725						730					735		
	Asn	Leu	Asp	Trp	Ser	Trp	Leu	Thr	Glu								
				740					745								

40 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2146 base pairs

(B) TYPE: nucleic acid

WO 99/01541

PCT/US98/13782

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	GTACCAGCAT CGGGAACCTG ATCTCAAAAT AGCAATTAAG TCTTGTCCG	60
	TACCAAAAAC AGAGAACGAT GGTGCCATGA AATCCAGATT ATGAAGAAGT TGAACCATGC	120
	CAATGTTGTA AAGGCCTGTG ATGTTCCCTGA AGAATTGAAT ATTTTGATTG ATGATGTGCC	180
	TCTTCTAGCA ATGGAATACT GTTCTGGAGG AGATCTCCGA AAGCTGCTCA ACAAACCAGA	240
10	AAATTGTTGT GGACTTAAAG AAAGCCAGAT ACTTTCTTTA CTAAGTGATA TAGGGTCTGG	300
	GATTCGATAT TTGCATGAAA ACAAATTAT ACATCGAGAT CTAAAACCTG AAAACATAGT	360
	TCTTCAGGAT GTTGGTGGAA AGATAATACA TAAATAAATT GATCTGGGAT ATGCCAAAGA	420
	TGTTGATCAA GGAAGTCTGT GTACATCTTT TGTGGGAACA CTGCAGTATC TGGCCCCAGA	480
	GCTCTTTGAG AATAAGCCTT ACACAGCCAC TGTTGATTAT TGGAGCTTTG GGACCATGGT	540
15	ATTTGAATGT ATTGCTGGAT ATAGGCCTTT TTTGCATCAT CTGCAGCCAT TTACCTGGCA	600
	TGAGAAGATT AAGAAGAAGG ATCCAAAGTG TATATTTGCA TGTGAAGAGA TGTGAGGAGA	660
	AGTTTCGTTT AGTAGCCATT TACCTCAACC AAATAGCCTT TGTAGTTTAA TAGTAGAACC	720
	CATGGAAAAC TGGCTACAGT TGATGTTGAA TTGGGACCCT CAGCAGAGAG GAGGACCTGT	780
	TGACCTTACT TTGAAGCAGC CAAGATGTTT TGTATTAATG GATCACATTT TGAATTTGAA	840
20	GATAGTACAC ATCCTAAATA TGACTTCTGC AAAGATAAATT TCTTTTCTGT TACCACCTGA	900
	TGAAAGTCTT CATTCACTAC AGTCTCGTAT TGAGCGTGAA ACTGGAATAA ATACTGGTTC	960
	TCAAGAACTT CTTTCAGAGA CAGGAATTTT TCTGGATCCT CGGAAACCAG CCTCTCAATG	1020
	TGTTCTAGAT GGAGTTAGAG GCTGTGATAG CTATATGGTT TATTTGTTTG ATAAAAGTAA	1080
	AACTGTATAT GAAGGGCCAT TTGCTTCCAG AAGTTTATCT GATTGTGTAA ATTATATTGT	1140
25	ACAGGACAGC AAAATACAGC TTCCAATTAT ACAGCTGCGT AAAGTGTGGG CTGAAGCAGT	1200
	GCACTATGTG TCTGGACTAA AAGAAGACTA TAGCAGGCTC TTTGAGGAC AAAGGGCAGC	1260
	AATGTTAAGT CTTCTTAGAT ATAATGCTAA CTTAACAAAA ATGAAGAACA CTTTGATCTC	1320
	AGCATCACAA CAACTGAAAG CTAAATTGGA GTTTTTTTCAC AAAAGCATTG AGCTTGACTT	1380
	GGAGAGATAC AGCGAGCAGA TGACGTATGG GATATCTTCA GAAAAAATGC TAAAAGCATG	1440
30	GAAAGAAATG GAAGAAAAGG CCATCCACTA TGCTGAGGTT GGTGTCATTG GATACCTGGA	1500
	GGATCAGATT ATGTCCTTTC ATGCTGAAAT CATGGAGCTA CAGAAGAGCC CCTATGGAAG	1560
	ACGTCAGGGA GACTTGATGG AATCTCTGGA ACAGCGTGCC ATTGATCTAT ATAAGCAGTT	1620
	AAAACACAGA CCTTCAGATC ACTCCTACAG TGACAGCACA GAGATGGTGA AAATCATTGT	1680
	GCACACTGTG CAGAGTCAGG ACCGTGTGCT CAAGGAGCGT TTTGGTCATT TGAGCAAGTT	1740
35	GTTGGGCTGT AAGCAGAAGA TTATTGATCT ACTCCCTAAG GTGGAAGTGG CCCTCAGTAA	1800
	TATCAAAGAA GCTGACAATA CTGTCATGTT CATGCAGGGA AAAAGGCAGA AAGAAATATG	1860
	GCATCTCCTT AAAATTGCCT GTACACAGAG TTCTGCCCGC TCTCTTGTAG GATCCAGTCT	1920
	AGAAGGTGCA GTAACCCCTC AAGCATAACG ATGGCTGGCC CCCGACTTAG CAGAACATGA	1980
	TCATTCTCTG TCATGTGTGG TAACTCCTCA AGATGGGGAG ACTTCAGCAC AAATGATAGA	2040
40	AGAAAATTTG AACTGCCTTG GCCATTTAAG CACTATTATT CATGAGGCAA ATGAGGAACA	2100
	GGGCAATAGT ATGATGAATC TTGATTGGAG TTGGTTAACA GAATGA	2146

WO 99/01541

PCT/US98/13782

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising SEQ ID NO:4, or at least a 10 residue domain thereof comprising at least one of Cys30, Leu604, Thr679, Ser680, Pro684, Thr686 and Ser678.
- 5 2. An isolated polypeptide according to claim 1, wherein said polypeptide has an activity selected from at least one of: a kinase or kinase inhibitory activity, a NIK-binding or binding inhibitory activity, an I κ B-binding or binding inhibitory activity and an NF κ B activating or inhibitory activity.
- 10 3. An isolated or recombinant first nucleic acid comprising a strand of SEQ ID NO:3, or a portion thereof having at least 24 contiguous bases of SEQ ID NO:3 and including at least one of bases 1-92, 1811, 1812, 1992, 1995, 2034, 2035, 2039, 2040, 2050, 2055 and 2060, sufficient to specifically hybridize with a second nucleic acid comprising the complementary strand of SEQ ID NO:3 in the presence of a third nucleic acid comprising
15 (SEQ ID NO:5).
4. A recombinant nucleic acid encoding a polypeptide according to claim 1.
5. A cell comprising a nucleic acid according to claim 4.
- 20 6. A method of making an isolated polypeptide according to claim 1, said method comprising steps: introducing a nucleic acid according to claim 4 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said nucleic acid is expressed as a transcript and said transcript is expressed as a translation product comprising
25 said polypeptide, and isolating said translation product.
7. A method of screening for an agent which modulates the interaction of an IKK polypeptide to a binding target, said method comprising the steps of:
incubating a mixture comprising:
30 an isolated polypeptide according to claim 1,
a binding target of said polypeptide, and

WO 99/01541

PCT/US98/13782

a candidate agent;

under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity;

5 detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target.

8. A method according to claim 7, wherein said binding target is a natural intracellular substrate and said reference and agent-biased binding affinity is detected as phosphorylation
10 of said substrate.

9. A method of screening for an agent which modulates the interaction of an IKK polypeptide to a binding target, said method comprising the steps of:

15 incubating a mixture comprising: an isolated polypeptide comprising SEQ ID NO: 2 or 4, or a deletion mutant thereof retaining I κ B kinase activity, an I κ B polypeptide comprising at least a six residue domain of a natural I κ B comprising at least one of Ser32 and Ser 36, and a candidate agent;

20 under conditions whereby, but for the presence of said agent, said polypeptide specifically phosphorylates said I κ B polypeptide at at least one of said Ser32 and Ser36 at a reference activity;

25 detecting the polypeptide-induced phosphorylation of said I κ B polypeptide at at least one of said Ser32 and Ser36 to determine an agent-biased activity, wherein a difference between the agent-biased activity and the reference activity indicates that said agent modulates the ability of said polypeptide to specifically phosphorylate a I κ B polypeptide.

10. A method for modulating signal transduction involving I κ B in a cell, said method comprising the step of modulating IKK- α (SEQ ID NO:4) kinase activity.

30 11. The method of claim 10, wherein said modulating step comprises contacting the cell with a serine/threonine kinase inhibitor.